Singapore-based biotechnology company MiRXES has raised $77 million in Series C funding led by CR-CP Life Science Fund, a joint venture between China Resources Group and Thailand’s Charoen Pokphand Group.
According to a statement, the round was also joined by global healthcare investment firm Rock Springs Capital and Singapore-based global investor EDBI, CCBI, Keytone Ventures, and financial institutions from the US, Singapore, China, Hong Kong and others.
